K

    Karyopharm Therapeutics Inc (KPTI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.06
    +0.19 (+10.16%)

    Market Cap: $42.41M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(21/40)
    Avg Surprise
    +3.43%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.31
    Range$-1.37 - $-1.26
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-1.21+7.7%
    60d ago$-1.21+7.7%
    30d ago$-1.21+7.7%
    7d ago$-1.46-10.8%
    Current$-1.31
    Revenue Consensus
    $34M
    Range$32M - $35M
    5 analysts
    Dec 31, 2026
    EPS Consensus$-1.70
    Range$-1.86 - $-1.53
    2 analysts
    Revenue Consensus
    $38M
    Range$34M - $41M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.70---
    Sep 26EST
    		-$-1.31---
    Jun 26
    		$-2.32$-1.53-51.63%Miss+43.0%
    Mar 26
    		$-1.24$-1.44+13.89%Beat+55.2%
    Dec 25
    		$-2.23$-2.00-11.50%Miss+38.1%
    Sep 25
    		$-3.82$-3.25-17.54%Miss+2.1%
    Jun 25
    		$-4.07$-3.91-4.09%Miss+6.2%
    Mar 25
    		$-2.77$-3.09+10.36%Beat+42.3%
    Dec 24
    		$-3.60$-4.03+10.67%Beat-900.0%
    Sep 24
    		$-3.90$-3.92+0.51%Beat+13.3%
    Jun 24
    		$-4.34$-4.47+2.91%Beat+0.2%
    Mar 24
    		$-4.80$-4.94+2.83%Beat-6.7%
    Dec 23
    		$-0.36$-0.31-16.13%Miss+94.4%
    Sep 23
    		$-4.50$-4.29-4.90%Miss+33.3%
    Jun 23
    		$-4.35$-5.04+13.69%Beat+53.2%
    Mar 23
    		$-4.50$-5.23+13.96%Beat+43.4%
    Dec 22
    		$-6.45$-5.38-19.89%Miss-193.5%
    Sep 22
    		$-6.75$-8.02+15.84%Beat+34.8%
    Jun 22
    		$-9.30$-9.55+2.62%Beat+12.7%
    Mar 22
    		$-7.95$-9.24+13.96%Beat+31.2%
    Dec 21
    		$6.90$-6.37+208.32%Beat+178.0%
    Sep 21
    		$-10.35$-10.27-0.78%Miss+5.5%
    Jun 21
    		$-10.65$-10.97+2.92%Beat-12.7%
    Mar 21
    		$-11.55$-10.75-7.44%Miss+1.3%
    Dec 20
    		$-8.85$-8.97+1.34%Beat+22.4%
    Sep 20
    		$-10.95$-10.48-4.48%Miss-9.0%
    Jun 20
    		$-9.45$-8.92-5.94%Miss+11.3%
    Mar 20
    		$-11.70$-10.29-13.70%Miss+28.4%
    Dec 19
    		$-11.40$-10.16-12.20%Miss-1087.5%
    Sep 19
    		$-10.05$-12.17+17.42%Beat+15.2%
    Jun 19
    		$-10.65$-14.29+25.47%Beat-18.3%
    Mar 19
    		$-16.35$-12.89-26.84%Miss-39.7%
    Dec 18
    		$-0.96$-0.85-12.94%Miss-20.0%
    Sep 18
    		$-11.85$-13.15+9.89%Beat-21.5%
    Jun 18
    		$-9.00$-12.03+25.19%Beat+6.2%
    Mar 18
    		$-11.70$-9.62-21.62%Miss-9.9%
    Dec 17
    		$-0.80$-0.65-23.08%Miss-23.1%
    Sep 17
    		$-9.75$-9.45-3.17%Miss+5.8%
    Jun 17
    		$-9.60$-9.77+1.74%Beat-
    Mar 17
    		$-10.65$-9.59-11.05%Miss-
    Dec 16
    		$-0.65$-0.66+1.52%Beat-
    Sep 16
    		$-10.35$-11.65+11.16%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.21EV/EBITDA-1.85x
    Price/FCF-0.91xFCF Yield-109.62%
    Profitability
    Profit Margin-153.30%Operating Margin-67.40%
    ROE-891.00%ROIC64.55%
    Financial Health
    Debt/Equity-0.46xInterest Coverage-1.03x
    Current Ratio0.79xQuick Ratio0.76x
    Trading Statistics
    Beta0.94Avg Volume1.60M
    52-Week High$10.9952-Week Low$1.79

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.93
    SMA 20$1.96
    SMA 50$5.88
    SMA 200$7.22
    EMA 10$2.02
    EMA 20$2.64
    EMA 50$4.73
    EMA 200$6.72

    MACD

    Line: -1.04Signal: -1.30Hist: 0.26

    ADX

    ADX: 53.6+DI: 13.8-DI: 37.7

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down60.0
    PSAR$1.79

    Bollinger Bands

    Upper Band$2.13
    Lower Band$1.79
    %B Position1701%(Upper)
    Band Width0.80

    RSI (14-Day)

    Oversold
    29.7

    Momentum Oscillators

    Stoch %K44.7
    Stoch %D39.1
    Williams %R-24.8
    ROC (10d)13.8%
    Momentum0.25
    CCI (20d)41.2
    MFI (14d)53.7

    Volatility Measures

    ATR (14d)$0.36(17.3%)
    StdDev (20d)0.08
    Hist Vol94.5%(High)

    Volume Flow

    VWAP$2.00
    OBV-27.9M
    AD Line-21.5M
    CMF (20d)-0.162

    Volume Metrics

    Avg Vol (20d)1.5M
    Vol Ratio1.4x
    VWMA (20d)$1.97

    Pivot Points

    R3$2.08
    R2$2.04
    R1$1.95
    Pivot Point$1.91
    S1$1.82
    S2$1.78
    S3$1.69

    Advanced Oscillators

    TSI-52.73
    Ultimate Osc48.9
    KST-542.32

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$33.43M$35.07M$34.08M$44.04M$37.93M$30.02M$30.54M$38.78M$42.79M$33.13M$33.75M$36.01M
    Cost of Revenue$1.08M$1.34M$1.48M$2.11M$1.05M$1.30M$1.33M$1.30M$1.47M$1.91M$1.49M$911,000
    Gross Profit$32.35M$33.72M$32.59M$41.93M$36.88M$28.71M$29.21M$37.48M$41.32M$31.21M$32.26M$35.10M
    Operating Expenses$54.87M$60.48M$50.44M$57.15M$61.27M$61.97M$60.49M$63.77M$69.44M$64.97M$70.07M$66.36M
    R&D$28.96M$33.80M$27.67M$30.54M$32.79M$34.62M$33.30M$36.13M$38.37M$35.42M$39.38M$35.55M
    SG&A$25.92M$26.68M$22.77M$26.61M$28.48M$27.35M$27.19M$27.63M$31.07M$29.55M$30.69M$30.80M
    Operating Income$-22,526,000$-26,760,000$-17,844,000$-15,220,000$-24,387,000$-33,256,000$-31,281,000$-26,283,000$-28,120,000$-33,759,000$-37,808,000$-31,260,000
    Interest Income$722,000$511,000$607,000$553,000$613,000$1.00M$1.48M$1.83M$1.93M$2.16M$2.52M$2.75M
    Interest Expense$13.14M$12.55M$74.98M$11.01M$11.23M$10.99M$11.20M$11.38M$-35,753,000$5.88M$6.21M$6.07M
    Income Before Tax$-67,023,000$-22,391,000$-102,265,000$-33,093,000$-37,212,000$-23,426,000$-30,889,000$-32,044,000$23.86M$-37,291,000$-41,707,000$-34,494,000
    Income Tax Expense$0$1,000$-67,000$34,000$40,000$36,000$-109,000$28,000$67,000$71,000$130,000$12,000
    Net Income$-67,023,000$-22,392,000$-102,198,000$-33,127,000$-37,252,000$-23,462,000$-30,780,000$-32,072,000$23.79M$-37,362,000$-41,837,000$-34,506,000
    EBITDA$-52,137,000$-7,973,000$-25,433,000$-19,754,000$-23,919,000$-11,017,000$-19,121,000$-20,532,000$-13,006,000$-34,181,000$-38,746,000$-31,822,000
    EBIT$-54,601,000$-10,349,000$-27,888,000$-22,638,000$-26,597,000$-13,432,000$-21,167,000$-22,491,000$-13,824,000$-33,563,000$-38,019,000$-31,171,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KPTI

    News

    Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option t...

    Karyopharm Therapeutics announced the closing of its public offering, including the full exercise of underwriters' option to purchase additional shares, resulting in gross proceeds of $172.5 million. The company plans to use these net proceeds to support the continued commercialization and clinical development of selinexor, as well as to advance other pipeline drug candidates and for general corporate purposes. The offering involved the issuance and sale of 7,187,500 shares of common stock at $24.00 per share.

    mx.advfn.com•8/24/26•
    Somewhat-Bullish

    Earnings Release: Here's Why Analysts Cut Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target To US$6.40

    Karyopharm Therapeutics Inc. (NASDAQ:KPTI) saw its share price drop after its latest quarterly results, despite revenue beating expectations. Analysts subsequently cut their consensus price target by 57% to US$6.40, reflecting concerns over increasing losses and a projected revenue decline that is worse than the industry average. The company is expected to continue experiencing significant losses in the coming year, with revenue forecast to fall by an annualized rate of 14% by the end of 2026.

    Simply Wall Street•8/16/26•
    Neutral

    Earnings Release: Here's Why Analysts Cut Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target To US$6.40

    Karyopharm Therapeutics Inc. (NASDAQ:KPTI) recently reported quarterly results, which saw revenues of US$33m beat expectations but statutory losses per share increase to US$2.32. Following these results, analysts have significantly cut their consensus price target for Karyopharm Therapeutics by 57% to US$6.40 per share, primarily due to concerns over ballooning losses and a forecast acceleration in revenue decline. The company's revenue is expected to fall at an annualized rate of 14% through 2026, performing worse than its industry peers.

    Simply Wall Street•8/16/26•
    Bearish

    RA Capital boosts Karyopharm (KPTI) stake to 9.99% beneficial ownership cap

    RA Capital Management, L.P. and its affiliated reporting persons have reported a 9.99% beneficial ownership stake in Karyopharm Therapeutics Inc. (KPTI) as of June 30, 2026. This stake, totaling 2,302,504 shares, is held through RA Capital Healthcare Fund, L.P., and is capped at 9.99% due to "Beneficial Ownership Blockers" in warrants. The filing, an amended passive investment disclosure (SCHEDULE 13G/A), details the shares and warrants held and outlines the shared voting and dispositive power among the reporting persons.

    Stock Titan•8/14/26•
    Somewhat-Bullish

    It's crunch time for Karyopharm as company faces potential default next month

    Karyopharm Therapeutics is facing a potential default next month due to depleted cash reserves and an upcoming debt payment. The company reported a significant loss in Q2 and has limited liquidity, but is negotiating with lenders and exploring financing and strategic alternatives. Karyopharm is also pursuing accelerated approval for an Xpovio label expansion for myelofibrosis, hoping to leverage existing infrastructure despite stagnant Xpovio sales and recent layoffs.

    Fierce Pharma•8/14/26•
    Bearish

    Frequently Asked Questions About KPTI

    Does KPTI pay dividends?
    Karyopharm Therapeutics Inc (KPTI) does not currently pay a regular dividend.
    What is KPTI's market cap?
    Karyopharm Therapeutics Inc (KPTI) has a market capitalization of $42.41M with a current stock price of $2.06.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In